Fenofibrate NDC 35561-249

NDC codes

FDA NDC Directory

Product NDC (as listed)35561-249Labeler and product segments. Claims need a package NDC.

Product NDC at billing width35561-0249Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package
35561-249-03	35561024903	500 TABLET, FILM COATED in 1 BOTTLE (35561-249-03)Marketed from Aug 7, 2025
35561-249-10	35561024910	30 TABLET, FILM COATED in 1 BOTTLE (35561-249-10)Marketed from Jan 1, 2021
35561-249-11	35561024911	90 TABLET, FILM COATED in 1 BOTTLE (35561-249-11)Marketed from Aug 15, 2025
35561-249-13	35561024913	500 TABLET, FILM COATED in 1 BOTTLE (35561-249-13)Marketed from Jan 1, 2021

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Fenofibrate
Generic name (nonproprietary): fenofibrate
Active ingredients: Fenofibrate — 48 mg/1
Dosage form: Tablet, Film coated
Route: Oral
Labeler: Bostal LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 208476
Marketing start: Jan 1, 2021
Listing expires: Dec 31, 2027
Identifiers: Product ID 35561-249_55835cb2-d0ae-161d-e063-6394a90ac6cbSPL ID 55835cb2-d0ae-161d-e063-6394a90ac6cbSPL set ID 7eb328d0-4e6f-4b24-ae85-68c2b3657569RxCUI 477560, 477562UNII U202363UOSUPC 0335561249101, 0335561250114, 0335561250107, 0335561249132, 0335561250138, 0335561249118
Pharmacologic class: Peroxisome Proliferator Receptor alpha Agonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N435561024903 followed by a unit qualifier and the quantity

Package 35561-0249-03. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jun 30, 2026.

Indications (excerpt from the label)

Fenofibrate tablets are peroxisome proliferator-activated receptors (PPARα) alpha agonist indicated as an adjunct to diet: To reduce elevated LDL-C, Total-C, TG and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia ( 1.1 ). For treatment of adult patients with severe hypertriglyceridemia ( 1.2 ). Limitations of Use: Fenofibrate was not shown to reduce coronary heart disease morbidity and mortality in patients with type 2 diabetes mellitus ( 5.1 ). 1.1 Primary Hypercholesterolemia or Mixed Dyslipidemia Fenofibrate tablets are indicated as adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total choles…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 208476

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 208476
Product	Strength	Form · route	Labeler	Product NDC
Fenofibrate	Fenofibrate 145 mg/1	Tablet, Film coatedOral	Bostal LLC	35561-250
Fenofibrate	Fenofibrate 145 mg/1	Tablet, Film coatedOral	Golden State Medical Supply, Inc.	51407-006
Fenofibrate	Fenofibrate 48 mg/1	Tablet, Film coatedOral	Golden State Medical Supply, Inc.	51407-005